Physician profile
Will Tanigaki
NPI 1427798636
$1,514.39
in general payments reported to CMS, 2019-2025
13 companies · $785 in 2025
The $785 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.42 · 2023: $305 · 2024: $404 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $200.74 | 2025 | |
| Ucb, INC. | $111.28 | 2025 | Rystiggo |
| Springworks Therapeutics, INC. | $95.18 | 2025 | Gomekli |
| Argenx US, INC. | $90.98 | 2025 | Vyvgart Hytrulo |
| Amgen INC. | $72.28 | 2024 | Uplizna |
| Csl Behring | $65.19 | 2025 | Hizentra |
| Abbvie INC. | $48.07 | 2025 | |
| Grifols USA, LLC | $42.60 | 2025 | Gamunex-C |
| Acadia Pharmaceuticals INC | $40.03 | 2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $24.93 | 2025 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $23.69 | 2025 | Wainua |
| Biogen, INC. | $22.12 | 2025 | Spinraza |
| Amicus Therapeutics, INC. | $19.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Will Tanigaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.